WealthShield Partners’s iShares Biotechnology ETF IBB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-44
Closed -$7.43K 488
2026
Q1
$7.43K Buy
44
+1
+2% +$171 ﹤0.01% 542
2025
Q4
$7.26K Hold
43
﹤0.01% 517
2025
Q3
$6.21K Hold
43
﹤0.01% 519
2025
Q2
$5.44K Hold
43
﹤0.01% 509
2025
Q1
$5.5K Sell
43
-145
-77% -$19.7K ﹤0.01% 495
2024
Q4
$24.9K Sell
188
-75
-29% -$10.5K ﹤0.01% 410
2024
Q3
$38.3K Hold
263
0.01% 396
2024
Q2
$36.1K Hold
263
0.01% 370
2024
Q1
$36.1K Sell
263
-400
-60% -$54.6K 0.01% 361
2023
Q4
$90.1K Buy
663
+24
+4% +$2.93K 0.01% 328
2023
Q3
$78.2K Hold
639
0.01% 353
2023
Q2
$81.1K Hold
639
0.01% 355
2023
Q1
$82.5K Buy
+639
New +$83.6K 0.01% 351
2020
Q4
Sell
-191
Closed -$26K 331
2020
Q3
$26K Buy
191
+71
+59% +$9.63K 0.01% 325
2020
Q2
$16K Buy
+120
New +$15.3K 0.01% 282
2019
Q4
Sell
-25
Closed -$2.79K 276
2019
Q3
$2K Hold
25
﹤0.01% 255
2019
Q2
$3K Hold
25
﹤0.01% 219
2019
Q1
$3K Hold
25
﹤0.01% 252
2018
Q4
$2K Buy
+25
New +$2.65K ﹤0.01% 231
2018
Q1
Sell
-207
Closed -$23K 246
2017
Q4
$23K Buy
+207
New +$22.1K 0.01% 173

Other funds holding IBB

WealthShield Partners's IBB Position: Q2 2026 in Review

WealthShield Partners sold out of iShares Biotechnology ETF (IBB) in Q2 2026, closing a stake of 44 shares — an estimated $7.43K sold.

WealthShield Partners first reported a position in IBB in Q4 2017 and held it in 20 quarters. The position peaked at $90.1K in Q4 2023. 957 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

  • WealthShield Partners reported no remaining iShares Biotechnology ETF position as of Q2 2026 after selling out during the quarter.
  • WealthShield Partners sold 44 iShares Biotechnology ETF shares in Q2 2026, an estimated $7.43K.
  • WealthShield Partners first reported a position in iShares Biotechnology ETF in Q4 2017 and held it in 20 quarters.
  • WealthShield Partners's iShares Biotechnology ETF position peaked at $90.1K in Q4 2023.
  • 957 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on WealthShield Partners's 13F filing for Q2 2026, filed 12 Aug 2026.